Savolitinib

Savolitinib

Clinical data
Other names	Volitinib
ATC code	L01EP03 ( WHO )
Identifiers
IUPAC name 3-[(1S)-1-Imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine
CAS Number	1313725-88-0
ChemSpider	34501055
UNII	2A2DA6857R
KEGG	D11139
ChEBI	CHEBI:231369
CompTox Dashboard (EPA)	DTXSID801111016
ECHA InfoCard	100.238.920
Chemical and physical data
Formula	C17H15N9
Molar mass	345.370 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21
InChI InChI=1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3/t11-/m0/s1 Key:XYDNMOZJKOGZLS-NSHDSACASA-N

Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca. ^[1] It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma. ^[2] It has been given conditional approval for these indication in China. ^[3]

References

1. "Savolitinib" (PDF). Statement on a Nonproprietary Name Adopted by the USAN Council. American Medical Association. 26 October 2016.
2. "Savolitinib - AstraZeneca/Hutchison China MediTech Limited". AdisInsight. Springer Nature Switzerland AG.
3. Markham A (September 2021). "Savolitinib: First Approval". Drugs. 81 (14): 1665–1670. doi:10.1007/s40265-021-01584-0. PMID   34455538. S2CID   237344020.